ARCA (Synonyms: Anti Reverse Cap Analog, 3´-O-Me-m7G(5')ppp(5')G) |
Catalog No.GC16608
One-Click Copy Product Info
|
ARCA is a 5′ cap analog that functions as an anti-reverse cap analog.
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
ARCA is a 5′ cap analog that functions as an anti-reverse cap analog. ARCA ensures that the cap is connected to the 5′ end of mRNA in the correct orientation during in vitro transcription. By introducing a methyl group at the 3′-OH position of m7G, ARCA ensures correct directional attachment to the 5′ end of mRNA and prevents reverse incorporation during in vitro transcription. ARCA enhances mRNA translation efficiency and stability. ARCA can be used for research on cancer, infectious diseases and mRNA vaccines[1-4].
References:
[1] Sun H, Song Y, Chen F, et al. An ArcA-Modulated Small RNA in Pathogenic Escherichia coli K1. Front Microbiol. 2020 Nov 23;11:574833.
[2] Fu T, Fan Z, Chen Y, et al. ArcA modulates multidrug resistance and compound susceptibility in Klebsiella pneumoniae through ArcB-independent regulation of the SMR efflux pump kpnEF. Microbiol Spectr. 2025 Nov 4;13(11):e0149925.
[3] Kowalska J, Wypijewska del Nogal A, et al. Synthesis, properties, and biological activity of boranophosphate analogs of the mRNA cap: versatile tools for manipulation of therapeutically relevant cap-dependent processes. Nucleic Acids Res. 2014;42(16):10245-64.
[4] Bednarczyk M, Peters JK, Kasprzyk R, et al. Fluorescence-Based Activity Screening Assay Reveals Small Molecule Inhibitors of Vaccinia Virus mRNA Decapping Enzyme D9. ACS Chem Biol. 2022 Jun 17;17(6):1460-1471.
Method for preparing correctly oriented cap-structured mRNA using ARCA[1]
This protocol is for reference only. Please adjust according to actual needs.
(1) Reagent preparation: dissolve ARCA in water or appropriate buffer to prepare a 0.5mM stock solution. Prepare an NTP mixture containing 0.5mM ATP, 0.5mM CTP, 0.5mM UTP and 0.1mM GTP (ARCA to GTP molar ratio 5:1). Prepare SP6 or T7 RNA polymerase, DNA template, RNase inhibitor and transcription buffer.
(2) In vitro transcription reaction system construction: add 600ng DNA template, 1U/μL RNase inhibitor, 0.5mM ATP/CTP/UTP, 0.1mM GTP and 0.5mM ARCA to the transcription buffer. Add SP6 or T7 RNA polymerase.
(3) mRNA synthesis: incubate at 37°C for 1 hour. Add 2μL DNase and incubate at 37°C for 20 minutes to remove template DNA. Purify the RNA product to obtain ARCA cap-structured mRNA with correct orientation.
(4) Translation verification of ARCA-capped mRNA: transfect ARCA-capped mRNA into HEK293 cells (DMEM+10%FBS; 37°C; 5%CO2), or add rabbit reticulocyte lysate and incubate at 30°C for 60 minutes. Evaluate translation efficiency by luciferase luminescence values. Detect remaining mRNA proportion in HEK293 cells by RT-qPCR to evaluate stability.
Precautions:
(1) To prevent RNA degradation, use RNase-free consumables throughout the experiment and perform operations on ice.
(2) For your safety and health, wear laboratory coats and disposable gloves during operation.
References:
[1] Kocmik I, Piecyk K, Rudzinska M, et al. Modified ARCA analogs providing enhanced translational properties of capped mRNAs. Cell Cycle. 2018;17(13):1624-1636.
| Cas No. | SDF | ||
| Synonyms | Anti Reverse Cap Analog, 3´-O-Me-m7G(5')ppp(5')G | ||
| Canonical SMILES | OC1C(COP([O-])(OP([O-])(OP([O-])(OCC2OC(N3C=[N+](C)C4=C3N=C(N)NC4=O)C(O)C2OC)=O)=O)=O)OC(N5C=NC6=C5N=C(N)NC6=O)C1O | ||
| Formula | C22H32N10O18P3 (free acid) | M.Wt | 817.4 g/mol (free acid) |
| Solubility | Storage | Store at -20°C | |
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.2234 mL | 6.117 mL | 12.2339 mL |
| 5 mM | 244.7 μL | 1.2234 mL | 2.4468 mL |
| 10 mM | 122.3 μL | 611.7 μL | 1.2234 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A liquid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 31 reference(s) in Google Scholar.)